Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFIWJ Sandborn, Colleen Marano, Silvio Danese et al.|Zeitschrift für Gastroenterologie|2019Cited by 7
Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs diseaseBE Sands, B. Feagan, Christopher Gasink et al.|Inflammatory Bowel Diseases|2011Cited by 5
Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFIBE Sands, WJ Sandborn, Laurent Peyrin‐Biroulet et al.|Zeitschrift für Gastroenterologie|2019Cited by 2
Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance StudyGert Van Assche, Laurent Peyrin‐Biroulet, Silvio Danese et al.|Zeitschrift für Gastroenterologie|2019Cited by 0